Overview

The Inova Type 2 Diabetes Mellitus Study

Status:
Withdrawn
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and effectiveness of the two different basal insulins commonly used for basal blood sugar control in the treatment of type 2 diabetes mellitus in patients who are hospitalized and require low doses of insulin: neutral protamine Hagedorn (NPH) insulin and glargine (Lantus®) insulin. Previous research has shown that both NPH insulin and glargine (Lantus®) insulin is safe and effective for the control of blood sugar in a type 2 diabetic patient. This research is being done because the costs of medications for diabetic patients are very expensive. Our goal with this research is to show that a less expensive insulin (NPH) is as safe and effective as a more expensive insulin [glargine (Lantus®)] in patients with type 2 diabetes mellitus who are in the hospital.
Phase:
N/A
Details
Lead Sponsor:
Inova Health Care Services
Treatments:
Insulin
Insulin Glargine
Insulin, Globin Zinc
Isophane Insulin, Human